Drug intelligence / Profile preview

WR-826647

Development stage: Phase 1
Lead developer: Walter Reed Army Institute of Research
Modality: Small Molecules

Overview

WR-826647 is a small molecule drug developed by the Walter Reed Army Institute of Research for the treatment of malaria. It belongs to a class of triazine compounds and has been evaluated in early phase clinical trials for its pharmacokinetics and bioavailability. The compound is being investigated as an antimalarial agent, with its primary therapeutic area being infectious diseases, specifically malaria. As of January 2025, it has reached Phase 1 clinical development[1][2][3][4].

Targets

DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on WR-826647.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WR-826647.

Explore the full profile